AstraZeneca's experimental heart treatment had warning signs for liver failure in a recent test, increasing the likelihood that the U.K. drugmaker will stop work on the product, analysts said.
The medicine, called AGI-1067, failed to meet the study's main goal, which looked at a range of complications including chest pain. While the product cut diabetes and reduced deaths from heart attacks and strokes, data showed a liver toxicity profile ``far too hazardous'' for approval, Gbola Amusa, analyst at Sanford Bernstein in London, wrote in a note to clients today.
Higher levels of a so-called marker for liver damage were found in the data presented at the American College of Cardiology, Amusa said.
A similar finding forced AstraZeneca to drop Exanta, a clot treatment.
The London-based company is studying the new data and has 45 days to decide whether to proceed with development with partner AtheroGenics Inc.
Hmm! Wonder which way they will jump?
More at Bloomberg
No comments:
Post a Comment